Meet TESSA: A New, Scalable, Plasmid-Free System for AAV Manufacture

Phacilitate
21 December 2021
SHARE NOW
Ryan Cawood, CSO at WuXi Advanced Therapies introduces TESSA – a ‘revolutionary’ technology for manufacturing AAV.

In this demo video, Ryan explains what TESSA technology – a novel, plasmid free approach to AAV manufacture – is and how it works. He introduces what effect TESSA-based AAV manufacture has on AAV yield and quality and outlines the benefit he sees this delivering to patients.

You can hear more from Ryan and about TESSA technology at Phacilitate Advanced Therapies week, where he will be discussing TESSA technology at 11:20am on Thursday 27 January, in the Industry 4.0 session.

Phacilitate member? Watch this video and join the conversation via the network.

Not yet a member?
Join Today.